Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.

Official title

EFfIcacy and Tolerability of FIXed Duration Teclistamab and Talquetamab FOR FRAIL Patients With Newly Diagnosed Multiple Myeloma (2 Cohort Study) - the EMN 37 FITFIX FOR FRAIL Trial

Overview

This is a multicenter, open-label phase II study with 2 parallel cohorts for frail patients with newly diagnosed multiple myeloma treated with daratumumab in combination with teclistamab and talquetamab. The main purpose of this study is to determine the progression free survival at 18 months in patients treated with teclistamab and daratumumab (Cohort 1) or talquetamab and daratumumab (Cohort 2).

Detailed description

This study will consist of 4 phases:

* Initial treatment phase where patients will receive fixed duration of Tec-Dara or Tal-Dara. * TFI. * Re-treatment phase, where patients with confirmed PD will continue treatment with Tec-Dara or Tal-Dara per their assignment in the initial treatment phase. * Post-treatment follow-up phase.

Interventions

• Drug Teclistamab
  Teclistamab will be administered via a subcutaneous injection (SC), fixed duration and will be retreated until disease progression or intolerable toxicity.
• Drug Talquetamab
  Talquetamab will be administered via a subcutaneous injection (SC), fixed duration and will be retreated until disease progression or intolerable toxicity.
• Drug Daratumumab
  Dartumumab will be administered via a subcutaneous injection (SC), fixed duration and will be retreated until disease progression or intolerable toxicity.

Primary outcome measures

• Progression Free Survival (PFS) per IMWG criteria [Time frame: 18 months]

Secondary outcome measures (12)

• Overall Survival (OS) [Time frame: 9 years]
• Minimal Residual Disease (MRD) negativity rate [Time frame: 18 months]
• Minimal Residual Disease (MRD) negative CR [Time frame: 18 months]
• Sustained Minimal Residual Disease (MRD) negative CR [Time frame: 9 years]
• IMWG best response [Time frame: 18 months]
• Time to response [Time frame: 9 years]
• Time to best response [Time frame: 9 years]
• Event free survival (EFS) [Time frame: 9 years]
• Progression Free Survival 2 (PFS2) [Time frame: 9 years]
• Time to Next Treatment (TNT) [Time frame: 9 years]
• Adverse Events [Time frame: 9 years]
• Discontinuation [Time frame: 9 years]

Eligibility criteria

Inclusion criteria

• Patient is ≥18 years of age and capable of giving informed consent and must sign an informed consent form (ICF), indicating that they understand the purpose of, and procedures required for, the study and is willing to participate in the study
• Newly diagnosed and treatment-naïve patients with a confirmed diagnosis of MM with measurable disease according to IMWG criteria
• Measurable disease defined as M-protein in the serum (≥1 g/dL) or serum free light chain assay ≥10 mg/dL \[≥100 mg/L\] and abnormal serum immunoglobulin kappa/lambda FLC ratio
• Frail according to the Simplified IMWG frailty index
• Have clinical laboratory values meeting defined range
• Patients of childbearing potential must agree to use adequate/highly effective contraception from the time of signing the informed consent form through 3 months after the last dose of study drug

Exclusion criteria

• Non-secretory MM or measurable disease by urine or plasmacytoma only
• Central nervous system involvement of myeloma
• Significant pulmonary dysfunction
• Stroke, transient ischemic attack, or seizure within 6 months of eligibility
• Evidence of active systemic viral, fungal, or bacterial infections, requiring systemic antimicrobial therapy
• HIV and Hepatitis infections
• Exclude for any of the following:

• Any history of malignancy other than MM which is considered at high risk of recurrence requiring treatment or a malignancy that has been treated with chemotherapy currently affecting bone marrow capacity.
• Any active malignancy (ie, progressing or requiring treatment change in the last 24 months) other than multiple myeloma.
• Active autoimmune disease requiring systemic immunosuppressive therapy within 6 months before eligibility
• Contraindications or life-threatening allergies, hypersensitivity, or intolerance to any study treatment or its excipients (refer to IB and most recently applicable RSI)
• Extensive radiotherapy within 14 days or focal radiation only within 7 days of eligibility
• Current or active therapy for multiple myeloma or received a cumulative dose corticosteroids equivalent to >40 mg dexamethasone within the 14 days prior to C1D1
• Received a live attenuated vaccine ≤4 weeks before eligibility. Non-live vaccines or non-replicating authorized for emergency use (eg, COVID-19) are allowed
• Received a strong CYP3A4 inducer or use of St. John's wort ≤5 half-lives prior to dosing
• Patient had major surgery or significant traumatic injury within 2 weeks prior to eligibility. Kyphoplasty or Vertebroplasty is not considered major surgery
• Have received an investigational drug (including investigation vaccines) or used an invasive investigational medical device <4 week or 5 PK half-lives, before eligibility or is currently enrolled in an interventional investigational study except if only long-term survival data are collected
• Concurrent medical or psychiatric condition or disease (eg, uncontrolled diabetes, alcohol or drug abuse, severe dementia or altered mental status), that is likely to interfere with study procedures or results, or that in the opinion of the investigator would constitute a hazard for participation in the study
• Any other issue that would impair the ability of the patient to receive or tolerate the planned treatment at the investigational site, to understand informed consent or any condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient (eg,, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

Italy · 14 centers

• IT-Ascoli Piceno-Ospedale Mazzoni [01-016] — Ascoli Piceno
• IT-Bari-A.O.U. Consorziale Policlinico - Medicina Interna [01-018] — Bari
• IT-Bergamo-A.O. Papa Giovanni XXIII [01-003] — Bergamo
• IT-Bologna-A.O.U. di Bologna - Policlinico S. Orsola Malpighi [01-004] — Bologna
• IT-Bolzano-Ospedale di Bolzano - Azienda Sanitaria dell'Alto Adige [01-021] — Bolzano
• IT-Como-Ospedale Classificato Valduce [01-104] — Como
• IT-Milano-Fondazione IRCCS Ca' Grande Ospedale Maggiore Policlinico [01-039] — Milan
• IT-Milano-Ospedale S. Carlo Borromeo [01-105] — Milan
• … and 6 more centers

Netherlands · 9 centers

• NL-Amsterdam-Vrije Universiteit Medical Center (VUMC) [02-007] — Amsterdam
• NL-Arnhem-Rijnstate Hospital [02-009] — Arnhem
• NL-Enschede-Medisch Spectrum Twente [02-024] — Enschede
• NL-Groningen-University Medical Center Groningen [02-030] — Groningen
• NL-Nieuwegein-S. Antonius Hospital [02-038] — Nieuwegein
• NL-Schiedam-Franciscus Vlietland Hospital [02-049] — Schiedam
• NL-Sittard-Geleen-Zuyderland Medical Center [02-058] — Sittard
• NL-Den Haag-Haga Ziekenhuis [02-016] — The Hague
• … and 1 more center

Spain · 4 centers

• ES-Barcelona-H.U. Vall d'Hebrón [06-002] — Barcelona
• ES-Las Palmas-H.U. de Gran Canaria Dr Negrín [06-030] — Las Palmas
• ES-Murcia-H.U. Virgen de la Arrixaca [06-016] — Murcia
• ES-Salamanca-H.U. de Salamanca [06-021] — Salamanca

Norway · 2 centers

• NO-Oslo-Oslo University Hospital [23-007] — Oslo
• NO-Tønsberg-Vestfold Hospital Trust [23-012] — Tønsberg

Identifiers

NCT: NCT07107529 · EMN37 · 2024-520433-76-00

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗